Likewise, loss of IHH, another SHH ligand, by in vivo CRISPR led to more aggressive tumour growth suggesting that IHH, rather than SHH, activates the pathway in stroma to drive its tumour-suppressive effects—a novel role for IHH in the lung. This evidence concerns the gene IHH and neoplasm.